

DOCKET NO.: PHRM0027-101/00159.US1  
SERIAL NO.: 09/738,022

PATENT  
FILED: December 15, 2000


**In the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

Please cancel claims 7-17 and 21-26 as being drawn to non-elected inventions.

**STATUS OF CLAIMS**

1. (original) A compound comprising the formula



wherein:

X and Y are, independently, F, H or CH<sub>3</sub>;


R<sup>1</sup> is H or I;

R<sup>2</sup> is H or OH;

R<sup>3</sup> is H or C<sub>1</sub>-C<sub>8</sub> alkyl;

L is a bond or -OCH<sub>2</sub>C(=O); and

Q is



wherein:

R<sup>4</sup> is H, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub> or cyclopropyl; and

DOCKET NO.: PHRM0027-101/00159.US1  
SERIAL NO.: 09/738,022

PATENT  
FILED: December 15, 2000


Z is O or S;

or a pharmaceutically acceptable salt thereof.

2. (original) A compound of claim 1 wherein X is F, Y is H, R<sup>3</sup> is H, and R<sup>4</sup> is CH<sub>3</sub>.
3. (original) A compound of claim 1 wherein said compound is 2-[4-[4-[(5S)-5-[(Acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl-4-azido-2-hydroxy-5-iodo-<sup>125</sup>I-benzoate.
4. (original) A compound of claim 1 wherein said compound is N-[[[(5S)-3-[4-[4-(4-Azido-2-hydroxy-5-iodo-<sup>125</sup>I-benzoyl)-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.
5. (original) A compound of claim 1 wherein said compound is 2-[4-[4-[(5S)-5-[(Acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-1-piperazinyl]-2-oxoethyl 4-azido-3-iodo-<sup>125</sup>I-benzoate.
6. (original) A compound of claim 1 wherein said compound is N-[[[(5S)-3-[4-[4-(4-Azido-3-iodo-<sup>125</sup>I-benzoyl)-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.

Claims 7-17 (cancelled)

18. (original) A method of using a compound comprising the formula



DOCKET NO.: PHRM0027-101/00159.US1  
SERIAL NO.: 09/738,022

PATENT  
FILED: December 15, 2000

wherein:

X and Y are, independently, F, H or CH<sub>3</sub>;


R<sup>8</sup> is H or I;

R<sup>9</sup> is H or OH;

R<sup>10</sup> is H or C<sub>1</sub>-C<sub>8</sub> alkyl;

L is a bond or -OCH<sub>2</sub>C(=O); and

Q is



wherein:

R<sup>11</sup> is H, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub> or cyclopropyl; and

Z is O or S;

or a pharmaceutically acceptable salt thereof, as a photoaffinity probe.

19. (original) The method of claim 18 comprising the steps:

contacting a cell or component thereof with said compound, wherein said compound is radiolabeled;

exposing said radiolabeled compound to light; and

detecting said radiolabel.

20. (original) The method of claim 19 further comprising contacting said cell or components thereof with a competitor compound.

Claims 21-26 (cancelled)